Bio-Rad acquires AbD Serotec
Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products, has announced that it has purchased AbD Serotec, a division of MorphoSys, for approximately €53 million in cash.
AbD Serotec is one of the world’s leading antibody manufacturers, offering over 15,000 antibodies, kits and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as other facilities in Germany and the US.
“We are pleased to have AbD Serotec join Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO.
“With AbD Serotec’s comprehensive catalogue of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA and cell sorting.”
ACRF funds three new cancer research facilities
Scientists at QIMR Berghofer, the Peter MacCallum Cancer Centre and the Bio21 Institute have...
Govt announces $1.89bn package for health and medical research
The Australian Government is investing in a "once-in-a-generation transformation of health...
Accreditation Matters announces further speakers, MC
Respected journalist and presenter Steve Liebmann has been confirmed as host and MC for the...
